Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations.

Hauser K, Negron C, Albanese SK, Ray S, Steinbrecher T, Abel R, Chodera JD, Wang L.

Commun Biol. 2018;1. pii: 70. doi: 10.1101/239012. Epub 2018 Jun 13.

2.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
4.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

5.

Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.

Kamasani S, Akula S, Sivan SK, Manga V, Duyster J, Vudem DR, Kancha RK.

Tumour Biol. 2017 May;39(5):1010428317701643. doi: 10.1177/1010428317701643.

PMID:
28475010
6.
7.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
8.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
9.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
10.

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL.

J Clin Invest. 2007 Sep;117(9):2562-9.

11.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

12.

Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.

Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H.

Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14.

PMID:
22005133
13.

ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.

Wang Z, Liu Z, Wu X, Chu S, Wang J, Yuan H, Roth M, Yuan YC, Bhatia R, Chen W.

PLoS Genet. 2014 Jun 26;10(6):e1004414. doi: 10.1371/journal.pgen.1004414. eCollection 2014 Jun. Erratum in: PLoS Genet. 2015 Mar;11(3):e1005033.

14.

Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.

Akram AM, Iqbal Z, Akhtar T, Khalid AM, Sabar MF, Qazi MH, Aziz Z, Sajid N, Aleem A, Rasool M, Asif M, Aloraibi S, Aljamaan K, Iqbal M.

Cancer Biol Ther. 2017 Apr 3;18(4):214-221. doi: 10.1080/15384047.2017.1294289. Epub 2017 Feb 21.

15.
16.

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC.

Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.

PMID:
23433665
17.

Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.

Retnakumari AP, Hanumanthu PL, Malarvizhi GL, Prabhu R, Sidharthan N, Thampi MV, Menon D, Mony U, Menon K, Keechilat P, Nair S, Koyakutty M.

Mol Pharm. 2012 Nov 5;9(11):3062-78. doi: 10.1021/mp300172e. Epub 2012 Oct 5.

PMID:
22971013
18.

Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance.

Rejali L, Poopak B, Hasanzad M, Sheikhsofla F, Varnoosfaderani AS, Safari N, Rabieipoor S.

Iran J Cancer Prev. 2015 May;8(3):e2334. doi: 10.17795/ijcp2334. Epub 2015 May 27.

19.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
20.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P.

Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.

Supplemental Content

Support Center